Hinova Pharmaceuticals Inc. announced that it has received $147,300,000 in a round of funding on October 2, 2020. The transaction included participation from CCB International Asset Management Ltd., Shenzhen Investment Holding Capital Co., Ltd., Hangzhou Tigermed Consulting Co.,Ltd (SZSE:300347), Huarong Rongde Asset Management Co., Ltd., Hongtai Capital Holdings, Infinity Ventures, Founder H Fund Co., Ltd., Sealand Innovation Capital Investment Management Co., Ltd. and DiNovA Venture Capital.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.05 CNY | +0.04% |
|
-4.48% | -48.05% |
26/04 | Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
08/04 | China Stocks Fall Ahead of March Economic Data Release | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-48.05% | 369M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- 688302 Stock
- News Hinova Pharmaceuticals Inc.
- Hinova Pharmaceuticals Inc. announced that it has received $147.3 million in funding from a group of investors